Quadrant Capital Group LLC raised its holdings in Qiagen NV (NYSE:QGEN) by 51.6% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,496 shares of the company’s stock after buying an additional 3,573 shares during the quarter. Quadrant Capital Group LLC’s holdings in Qiagen were worth $418,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc grew its holdings in shares of Qiagen by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 6,627,163 shares of the company’s stock worth $251,037,000 after purchasing an additional 128,125 shares in the last quarter. Morgan Stanley grew its holdings in shares of Qiagen by 16.3% during the 3rd quarter. Morgan Stanley now owns 1,468,052 shares of the company’s stock worth $55,611,000 after purchasing an additional 205,698 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of Qiagen by 2.0% during the 4th quarter. State of Alaska Department of Revenue now owns 23,547 shares of the company’s stock worth $811,000 after purchasing an additional 463 shares in the last quarter. Advisors Capital Management LLC acquired a new stake in shares of Qiagen during the 4th quarter worth approximately $272,000. Finally, Bank of Montreal Can lifted its position in shares of Qiagen by 9.2% during the 4th quarter. Bank of Montreal Can now owns 890,316 shares of the company’s stock worth $30,672,000 after buying an additional 74,791 shares during the period. 64.24% of the stock is currently owned by hedge funds and other institutional investors.
QGEN traded up $0.19 during trading on Wednesday, hitting $38.70. The company’s stock had a trading volume of 749,003 shares, compared to its average volume of 1,325,076. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.52 and a current ratio of 1.69. Qiagen NV has a 12 month low of $32.33 and a 12 month high of $41.55. The company has a market cap of $8.72 billion, a price-to-earnings ratio of 28.88, a PEG ratio of 2.22 and a beta of 0.88.
Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.01. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The firm had revenue of $348.70 million during the quarter, compared to the consensus estimate of $351.68 million. During the same quarter in the previous year, the company posted $0.26 EPS. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. As a group, research analysts predict that Qiagen NV will post 1.43 EPS for the current fiscal year.
Several equities analysts recently commented on the company. Zacks Investment Research downgraded Qiagen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 9th. Deutsche Bank restated a “buy” rating on shares of Qiagen in a research report on Friday, April 12th. UBS Group assumed coverage on Qiagen in a research report on Friday, March 15th. They set a “neutral” rating and a $42.00 target price for the company. Finally, Goldman Sachs Group restated a “buy” rating on shares of Qiagen in a research report on Tuesday, May 7th. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Qiagen currently has a consensus rating of “Buy” and an average target price of $41.71.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Read More: Coverage Ratio
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.